Renaissance Technologies LLC raised its holdings in shares of Xenon Pharmaceuticals Inc (NASDAQ:XENE) by 70.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 489,500 shares of the biopharmaceutical company’s stock after acquiring an additional 201,500 shares during the quarter. Renaissance Technologies LLC owned approximately 3.45% of Xenon Pharmaceuticals worth $4,503,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of the business. Kovack Advisors Inc. bought a new stake in Xenon Pharmaceuticals during the second quarter valued at about $113,000. Spark Investment Management LLC raised its holdings in Xenon Pharmaceuticals by 105.5% during the second quarter. Spark Investment Management LLC now owns 26,100 shares of the biopharmaceutical company’s stock valued at $240,000 after acquiring an additional 13,400 shares during the period. NJ State Employees Deferred Compensation Plan raised its holdings in Xenon Pharmaceuticals by 150.0% during the second quarter. NJ State Employees Deferred Compensation Plan now owns 50,000 shares of the biopharmaceutical company’s stock valued at $460,000 after acquiring an additional 30,000 shares during the period. JBF Capital Inc. bought a new stake in Xenon Pharmaceuticals during the second quarter valued at about $368,000. Finally, State of New Jersey Common Pension Fund D raised its holdings in Xenon Pharmaceuticals by 138.6% during the second quarter. State of New Jersey Common Pension Fund D now owns 155,100 shares of the biopharmaceutical company’s stock valued at $1,427,000 after acquiring an additional 90,100 shares during the period. 47.26% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts have commented on XENE shares. BidaskClub raised Xenon Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 5th. Stifel Nicolaus raised their price target on Xenon Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Jefferies Financial Group reissued a “buy” rating and set a $16.00 price target on shares of Xenon Pharmaceuticals in a report on Friday, August 10th. Finally, Zacks Investment Research cut Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 11th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Xenon Pharmaceuticals has an average rating of “Buy” and a consensus target price of $14.33.
Shares of Xenon Pharmaceuticals stock opened at $11.13 on Wednesday. The stock has a market cap of $254.24 million, a PE ratio of -6.57 and a beta of 0.87. The company has a quick ratio of 20.83, a current ratio of 20.83 and a debt-to-equity ratio of 0.41. Xenon Pharmaceuticals Inc has a twelve month low of $2.10 and a twelve month high of $15.92.
Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.04. Analysts anticipate that Xenon Pharmaceuticals Inc will post -1.33 earnings per share for the current fiscal year.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies.
Featured Story: Retained Earnings
Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc (NASDAQ:XENE).
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.